Transcript of Earnings Call - Q1 FY27

AI summary - Q1 FY27 revenue grew 22.8% y-y to INR 2,580 Cr; EBITDA up 25.8% to INR 508 Cr with 19.7% margin (+50 bps); PAT rose 36.2% to INR 292 Cr - India business grew 10.2% y-y to INR 1,095 Cr, returning to double-digit growth; Zuventus consolidation phase nearly complete - International revenue grew 34.2% y-y to INR 1,485 Cr; Europe +32.8%, Canada +24.6%, Rest of World +44.8% driven by ARV segment - R&D investments at INR 90 Cr (3.5% of revenue), expected to rise to 4-5% of revenue in FY27 - FY27 guidance: low to mid-teen revenue growth, 70-100 bps EBITDA margin expansion - Net debt INR 1,103 Cr as of June 30, expected to rise due to acquisitions, net cash targeted by FY28 - New product approvals 15+ in quarter; focus on biologics, complex injectables, liposomal platform - Signed royalty-free license with MSD for generic oral HIV pill in 129 countries; advancing ARV portfolio - Domestic organic growth impacted by Zuventus consolidation; expected to align with or exceed industry growth from Q2 onwards - Gross margin around 59% in FY27 due to business mix; targeting 60-61% range long term - Semaglutide (Poviztra) gaining traction; market competitive with many brands, expect growth over 3-6 months - Management confident in execution, acceleration in India, and technology-driven international growth